Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Escola Nacional de Saude Publica, Rio de Janeiro
Seroconversion greater than 98% after yellow fever vaccination
October 26th, 2005
Researchers report the results of a randomized, placebo-controlled trial on the reactogenicity of yellow fever vaccines in a recent issue of Revista de Saude Publica. In a recently published article, scientists in Brazil conducted a study "to compare the reactogenicity of three yellow fever (YF) vaccines from WHO-17D and Brazilian 17DD substrains (different seed-lots) and placebo. The study involved 1,087 adults eligible for YF vaccine in Rio de Janeiro, Brazil. Vaccines produced by Bio-Manguinhos, Fiocruz (Rio de Janeiro, Brazil) were administered (day 0) following standardized procedures adapted to allow blinding and blocked randomization of participants to...
Source: Elder Law Weekly (2005-10-26)
|
